SCHEMBL5835342

SCHEMBL5835342

CCc1ccc(S(=O)(=O)Nc2ccc(Cl)c(OC3CCN(C)C3)c2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 13/20 0.62
MAPT P10636 4/20 0.53
ALDH1A1 P00352 2/20 0.53
LMNA P02545 1/20 0.53
POLB P06746 1/20 0.53
HPGD P15428 1/20 0.53
XBP1 P17861 1/20 0.53
HTT P42858 1/20 0.53
UCHL1 P09936 1/20 0.44
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
DRD2 P14416 1/20 0.43
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43
CYP2C19 P33261 1/20 0.43
DRD3 P35462 1/20 0.43
HTR6 P50406 1/20 0.43
TP53 P04637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5835336 1.00 UTS2R (0.62) UTS2RMAPTALDH1A1LMNAPOLB
SCHEMBL5836461 0.91 UTS2R (0.58) UTS2RLMNAPOLBCYP1A2CYP3A4
SCHEMBL5836456 0.91 UTS2R (0.58) UTS2RLMNAPOLBCYP1A2CYP3A4
SCHEMBL8342919 0.90 UTS2R (0.66) UTS2RMAPTALDH1A1LMNAHTT
SCHEMBL8342926 0.89 UTS2R (0.65) UTS2RMAPTALDH1A1LMNAPOLB
SCHEMBL6823022 0.88 UTS2R (0.64) UTS2RMAPTALDH1A1LMNAPOLB
SCHEMBL8342609 0.88 UTS2R (0.64) UTS2RMAPTALDH1A1LMNAHTT
SCHEMBL8340488 0.88 UTS2R (0.69) UTS2RMAPTALDH1A1LMNAHTT
SCHEMBL6823026 0.88 UTS2R (0.64) UTS2RMAPTALDH1A1LMNAPOLB
SCHEMBL5835458 0.87 UTS2R (0.63) UTS2RMAPTALDH1A1LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7026349-B2 Sulfonamides SMITHKLINE BEECHAM CORPORATION (US) 2006-04-11 US claimed
US-20040152906-A1 Sulfonamides SHELL OIL COMPANY 2004-08-05 US claimed
US-7026349-B2 Sulfonamides SMITHKLINE BEECHAM CORPORATION (US) 2006-04-11 US disclosed
EP-1385507-A4 SULFONAMIDES SMITHKLINE BEECHAM CORP (US) 2005-11-23 EP disclosed
US-20040152906-A1 Sulfonamides SHELL OIL COMPANY 2004-08-05 US disclosed
EP-1385507-A1 SULFONAMIDES SmithKline Beecham Corporation (US) 2004-02-04 EP disclosed
WO-2002089792-A1 SULFONAMIDES SMITHKLINE BEECHAM CORPORATION (US) 2002-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152906-A1 Sulfonamides UTS2R, PRSS2, STS UTS2R 1/4885MAPT 2260/4885ALDH1A1 3733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.